Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Brain, Behavior, and Immunity Year : 2020

Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression

Richard Bazinet
  • Function : Author
Adam Metherel
  • Function : Author
Chuck Chen
  • Function : Author
Agnès Nadjar
Corinne Joffre
Sophie Layé

Abstract

The results of several meta-analyses suggest that eicosapentaenoic acid (EPA) supplementation is therapeutic in managing the symptoms of major depression. It was previously assumed that because EPA is extremely low in the brain it did not cross the blood-brain barrier and any therapeutic effects it exerted would be via the periphery. However, more recent studies have established that EPA does enter the brain, but is rapidly metabolised following entry. While EPA does not accumulate within the brain, it is present in microglia and homeostatic mechanisms may regulate its esterification to phospholipids that serve important roles in cell signaling. Furthermore, a variety of signaling molecules from EPA have been described in the periphery and they have the potential to exert effects within the brain. If EPA is confirmed to be therapeutic in major depression as a result of adequately powered randomized clinical trials, future research on brain EPA metabolism could lead to the discovery of novel targets for treating or preventing major depression.
No file

Dates and versions

hal-03171047 , version 1 (16-03-2021)

Identifiers

Cite

Richard Bazinet, Adam Metherel, Chuck Chen, Saame Raza Shaikh, Agnès Nadjar, et al.. Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression. Brain, Behavior, and Immunity, 2020, 85, pp.21-28. ⟨10.1016/j.bbi.2019.07.001⟩. ⟨hal-03171047⟩
12 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More